Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sunrun Inc (RUN) vs Smith & Nephew plc (SNN) Price & Performance

Sunrun IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Sunrun Inc vs Smith & Nephew plc — how do they compare? Sunrun Inc trades at $8.79 (market cap $2.22B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Smith & Nephew plc is far larger — about 5.2× Sunrun Inc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.

RUNSNN
Market Cap
$2.22B$11.63B
Sector
TechnologyHealth
52-Week High
$21.41$38.53
52-Week Low
$8.37$27.80
Enterprise Value
$16.74B$14.66B
Dividend Yield
2.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sunrun Inc

Sunrun (RUN) trades at $9.22, up 3.71% today, but faces a bearish technical trend with resistance at $10. The company shows mixed fundamentals: it beat Q2 2026 EPS estimates ($0.42 actual vs. $0.23 expected) but cut full-year guidance, contributing to a 46% stock decline. Revenue is projected to grow to $3.5B in 2026, yet net income margin may drop to 11.59%. Recent news highlights a partnership with Voltus for AI hyperscaler energy capacity, offering a potential growth catalyst amid operational challenges.

The outlook is cautious; RUN appears undervalued with a P/E of 6.27 and P/B of 0.64, but risks include weak cash flow from operations (-$421M in 2025) and high debt. Analyst consensus is bullish (62% buy ratings) with a $14.70 price target, implying 59% upside, though execution on subscriber growth and margin recovery is critical for realizing gains.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.

Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.

Returns comparison

Trailing returns across standard periods

About Sunrun Inc

Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.

Read more on RUN

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN